Abstract
Topical therapy is the mainstay of treatment for patients with mild-to-moderate psoriasis. Currently available topical agents generally only produce short-term relief and the condition recurs when treatment is stopped. Tazarotene is a new generation synthetic retinoid with specificity for retinoic acid receptors (RARs) that is available in Germany and has recently been approved in Canada and in the US as a once-daily treatment for patients with stable plaque psoriasis and facial acne vulgaris. Results from several Allergan-sponsored studies examining tazarotene’s pharmacology and clinical use in patients with stable plaque psoriasis were presented at the 19th World Congress of Dermatology [ Sydney, Australia; June 1997 ].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
